Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma()

A majority of cases of high-risk neuroblastoma, an embryonal childhood cancer, are driven by MYC or MYCN-driven oncogenic signaling. While considered to be directly “undruggable” therapeutically, MYC and MYCN can be repressed transcriptionally by inhibition of Bromodomain-containing protein 4 (BRD4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Felgenhauer, Joshua, Tomino, Laura, Selich-Anderson, Julia, Bopp, Emily, Shah, Nilay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111011/
https://www.ncbi.nlm.nih.gov/pubmed/30153557
http://dx.doi.org/10.1016/j.neo.2018.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111011/
https://www.ncbi.nlm.nih.gov/pubmed/30153557
http://dx.doi.org/10.1016/j.neo.2018.08.002

Ejemplares similares